ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1MRNA | MODERNA INC | Healthcare | $93.61B | 44.94% |
2BAX | BAXTER INTERNATIONAL INC | Healthcare | $13.32B | 6.39% |
3ALGN | ALIGN TECHNOLOGY INC | Healthcare | $11.77B | 5.65% |
4SYRE | SPYRE THERAPEUTICS INC | Healthcare | $9.77B | 4.69% |
5TXG | 10X GENOMICS INC | Healthcare | $7.77B | 3.73% |
6KOD | KODIAK SCIENCES INC | Healthcare | $6.80B | 3.27% |
7ERAS | ERASCA INC | Healthcare | $5.52B | 2.65% |
8RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.99B | 1.92% |
9OGN | ORGANON & CO | Healthcare | $3.65B | 1.75% |
10IOVA | IOVANCE BIOTHERAPEUTICS INC | Healthcare | $3.53B | 1.69% |
11NEOG | NEOGEN CORP | Healthcare | $2.44B | 1.17% |
12NEO | NEOGENOMICS INC | Healthcare | $2.14B | 1.03% |
13VIR | VIR BIOTECHNOLOGY INC | Healthcare | $2.08B | 1.00% |
14MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $2.00B | 0.96% |
15AZTA | AZENTA INC | Healthcare | $1.92B | 0.92% |
16AGL | AGILON HEALTH INC | Healthcare | $1.85B | 0.89% |
17XRAY | DENTSPLY SIRONA INC | Healthcare | $1.83B | 0.88% |
18SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $1.62B | 0.78% |
19OMCL | OMNICELL INC | Healthcare | $1.61B | 0.77% |
20TDOC | TELADOC HEALTH INC | Healthcare | $1.58B | 0.76% |
21NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.48B | 0.71% |
22NVAX | NOVAVAX INC | Healthcare | $1.45B | 0.69% |
23AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.44B | 0.69% |
24KRSA | KORSANA BIOSCIENCES INC | Healthcare | $1.42B | 0.68% |
25NVCR | NOVOCURE LTD | Healthcare | $1.37B | 0.66% |
26DMRA | DAMORA THERAPEUTICS INC | Healthcare | $1.36B | 0.66% |
27STAA | STAAR SURGICAL CO | Healthcare | $1.34B | 0.65% |
28CMPS | COMPASS PATHWAYS PLC | Healthcare | $1.29B | 0.62% |
29TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.22B | 0.59% |
30VOR | VOR BIOPHARMA INC | Healthcare | $1.19B | 0.57% |
31IART | INTEGRA LIFESCIENCES HOLDINGS CORP | Healthcare | $1.12B | 0.54% |
32JBIO | JADE BIOSCIENCES INC | Healthcare | $1.01B | 0.48% |
33SLDB | SOLID BIOSCIENCES INC | Healthcare | $781M | 0.38% |
34QDEL | QUIDELORTHO CORP | Healthcare | $729M | 0.35% |
35CTKB | CYTEK BIOSCIENCES INC | Healthcare | $722M | 0.35% |
36FLGT | FULGENT GENETICS INC | Healthcare | $694M | 0.33% |
37DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $663M | 0.32% |
38CLYM | CLIMB BIO INC | Healthcare | $639M | 0.31% |
39SGHT | SIGHT SCIENCES INC | Healthcare | $611M | 0.29% |
40SRZN | SURROZEN INC | Healthcare | $604M | 0.29% |
41SENS | SENSEONICS HOLDINGS INC | Healthcare | $550M | 0.26% |
42CBIO | CRESCENT BIOPHARMA INC | Healthcare | $534M | 0.26% |
43TKNO | ALPHA TEKNOVA INC | Healthcare | $522M | 0.25% |
44RCEL | AVITA MEDICAL INC | Healthcare | $509M | 0.24% |
45ARVN | ARVINAS INC | Healthcare | $450M | 0.22% |
46AVTX | AVALO THERAPEUTICS INC | Healthcare | $445M | 0.21% |
47PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $423M | 0.20% |
48LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $385M | 0.18% |
49ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $326M | 0.16% |
50AGEN | AGENUS INC | Healthcare | $311M | 0.15% |
51EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $303M | 0.15% |
52FTH | FAETH THERAPEUTICS INC | Healthcare | $275M | 0.13% |
53QTTB | Q32 BIO INC | Healthcare | $264M | 0.13% |
54ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $243M | 0.12% |
55DTIL | PRECISION BIOSCIENCES INC | Healthcare | $225M | 0.11% |
56GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $224M | 0.11% |
57AMWL | AMERICAN WELL CORP | Healthcare | $207M | 0.10% |
58TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.10% |
59KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.09% |
60KRRO | KORRO BIO INC | Healthcare | $196M | 0.09% |
61RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $194M | 0.09% |
62ANIK | ANIKA THERAPEUTICS INC | Healthcare | $185M | 0.09% |
63STRO | SUTRO BIOPHARMA INC | Healthcare | $159M | 0.08% |
64INGN | INOGEN INC | Healthcare | $146M | 0.07% |
65CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.06% |
66BDSX | BIODESIX INC | Healthcare | $109M | 0.05% |
67IMUX | IMMUNIC INC | Healthcare | $106M | 0.05% |
68JYNT | JOINT CORP | Healthcare | $92M | 0.04% |
69RLYB | RALLYBIO CORP | Healthcare | $84M | 0.04% |
70ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $81M | 0.04% |
71GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.03% |
72XLO | XILIO THERAPEUTICS INC | Healthcare | $58M | 0.03% |
73COCH | ENVOY MEDICAL INC | Healthcare | $53M | 0.03% |
74YARW | YARROW BIOSCIENCE INC | Healthcare | $52M | 0.03% |
75ELOX | ELOXX PHARMACEUTICALS INC | Healthcare | $52M | 0.02% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $208.31B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 84% toward Large, 78% toward Growth. +12% unclassified (15 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 2002 → November 2026; the right-hand end is the same value as the box’s dot. 75 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
No more than 25% of total assets may be invested in the securities of any one issuer.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T063725 rates=20261113T063725
Measured on the 2026-11 formation date across 75 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 287 monthly observations · about 2.9 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (22 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 109.8% | 76.2% |
| 3 yearsp.a. | 37.5% | 14.4% |
| 5 yearsp.a. | 15.6% | 7.8% |
| 10 yearsp.a. | 8.8% | -2.7% |
| Since inceptionp.a. | 10.8% | -0.2% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 114.6% | 77.0% |
| 2025 | 18.6% | -8.2% |
| 2024 | -11.6% | -19.2% |
| 2023 | -3.0% | -23.6% |
| 2022 | -5.8% | 46.3% |
| 2021 | -10.9% | -13.6% |
| 2020 | -4.2% | -33.8% |
| 2019 | 17.0% | -6.9% |
| 2018 | -22.3% | -26.1% |
| 2017 | 47.8% | 32.4% |
| 2016 | -9.6% | 14.9% |
| 2015 | 12.8% | -1.3% |
| 2014 | 33.7% | 4.8% |
| 2013 | 67.4% | 8.9% |
| 2012 | 20.5% | -7.1% |
| 2011 | 12.3% | 15.1% |
| 2010 | 4.0% | 5.2% |
| 2009 | 17.6% | 5.6% |
| 2008 | -19.4% | 4.8% |
| 2007 | 3.1% | -0.7% |
| 2006 | 6.8% | 7.3% |
| 2005 | 6.4% | -11.0% |
| 2004 | 8.8% | -6.5% |
| 2003 | 28.0% | -12.8% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Long-Term Reversal Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Long-Term Reversal signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.